Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Dartmouth-Hitchcock Medical Center
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center